Gene therapy to rescue retinal degeneration caused by mutations in rhodopsin

Brian P. Rossmiller, Renee C. Ryals, Alfred S. Lewin

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Retinal gene therapy has proven safe and at least partially successful in clinical trials and in numerous animal models. Gene therapy requires characterization of the progression of the disease and understanding of its genetic cause. Testing gene therapies usually requires an animal model that recapitulates the key features of the human disease, though photoreceptors and cells of the retinal pigment epithelium produced from patient-derived stem cells may provide an alternative test system for retinal gene therapy. Gene therapy also requires a delivery system that introduces the therapeutic gene to the correct cell type and does not cause unintended damage to the tissue. Current systems being tested in the eye are nanoparticles, pseudotyped lentiviruses, and adeno-associated virus (AAV) of various serotypes. Here, we describe the techniques of AAV vector design as well as the in vivo and ex vivo tests necessary for assessing the efficacy of retinal gene therapy to treat retinal degeneration caused by mutations in the rhodopsin gene.

Original languageEnglish (US)
Pages (from-to)391-410
Number of pages20
JournalMethods in Molecular Biology
StatePublished - 2015


  • Adeno-associated virus
  • Autosomal dominant retinitis pigmentosa
  • Electroretinography
  • Intravitreal injection
  • Inverted terminal repeat
  • Mouse model
  • Optical coherence tomography
  • Outer nuclear layer
  • Rhodopsin
  • Subretinal injection

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics


Dive into the research topics of 'Gene therapy to rescue retinal degeneration caused by mutations in rhodopsin'. Together they form a unique fingerprint.

Cite this